In about 10% of sporadic tumors, ALK amplification is seen, which is often co-amplified with MYCN. Determining the underlying drivers of neuroblastoma tumorigenesis provides important information about prognosis (MYCN amplification is associated with aggressive clinical behavior) and precision medicine (ALK mutations). Here, MYCN is linked to neuroblastoma.